Anti-il36r antibodies
一种抗体、抗原的技术,应用在抗体、抗炎剂、抗受体/细胞表面抗原/细胞表面决定因子免疫球蛋白等方向,能够解决可用治疗有限等问题
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
preparation example Construction
[0130] Production of Human Antibodies
[0131] Methods for producing human antibodies in transgenic mice are known in the art. In the context of the present invention, any such known methods may be used to prepare human antibodies that specifically bind IL36R (eg IL1RL2). In certain embodiments of the invention, antibodies of the invention are obtained from antibodies immunized with IL36R (e.g., IL1RL2 polypeptides or immunogenic fragments thereof) or with live attenuated or inactivated viruses or with DNA encoding proteins or fragments thereof. mice. Alternatively, IL36R can be produced using standard biochemical techniques, and modified and used as an immunogen. In certain embodiments of the invention, the immunogen may be an IL36R (eg, IL1RL2) polypeptide vaccine. In certain embodiments, one or more booster injections may be administered. In certain embodiments, the immunogen may be a recombinant IL36R polypeptide (eg, IL1RL2) expressed in E. coli or in any other eukary...
example
[0204] The following examples are set forth to provide those of ordinary skill in the art
[0205] A full disclosure and description of how to make and use the methods and compositions of the invention,
[0206] and the examples are not intended to limit
[0207] What the inventors consider to be the scope of their invention.
example 1
[0208] Example 1 : Generation of human antibodies that specifically bind IL-36R
[0209] By immunizing VELOCIMMUNE mice (i.e., mice engineered to contain DNA encoding human immunoglobulin heavy chain and kappa light chain variable regions) with a DNA immunogen containing the full-length IL36R (IL-1RL2) sequence, Obtain anti-IL36R antibody. Antibodies were monitored by IL36R-specific immunoassays, and fully human anti-IL36R antibodies were isolated and purified. The V of the antibody generated as described herein H and V L Two exemplary comparisons between its germline counterparts are set forth in figure 1 and figure 2 middle.
[0210] Table 1. Immunoglobulin chain sequences of the invention*
[0211]
[0212]
[0213]*corresponds to V H , CDR-H1, CDR-H2, CDR-H3, V L , CDR-L1, CDR-L2 and CDR-L3 numbers refer to the SEQ ID NOs set forth herein. "PEP" refers to an amino acid sequence; "DNA" refers to a nucleotide sequence.
[0214] SEQ ID NO:1
[0215] GAAGT...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 



